Trial suggests Erbitux has first-line potential

Share this article:
ImClone and Bristol-Myers Squibb said results of a phase III trial of Erbitux support its use as a first-line treatment for metastatic colon cancer. The drug delayed progression of the disease in patients who took it in combination with a chemotherapy as an initial line of treatment, they said. The ability to be used in earlier lines of cancer would lend Erbitux a marketing edge. ImClone and BMS, which share US marketing rights to Erbitux (cetuximab), have faced greater competition since the 2006 launch of Vectibix (panitumumab) by Amgen. Both drugs are approved for metastatic colon cancer in combination with chemotherapy in patients who have failed other therapies. Amgen, bent on grabbing market share, has priced Vectibix at a 20% discount to Erbitux. The findings also provide a boost for Merck KGaA, ImClone’s Erbitux marketing partner outside of North America. The German firm officially launched its new pharmaceuticals business, Merck Serono, following the acquisition of Swiss-based biotech firm Serono. Merck conducted the phase III study. Analysts, however, said a lack of details about the Erbitux data make it difficult to compare the benefits of the two drugs at this stage. That didn't prevent Wall Street from sending ImClone shares up more than 8%, according to Reuters. Shares of Merck KGaA rose as much as 4.4% in early trading, following the announcement.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...